Earnings Call · Q2 FY2024·2024-08-11

Q2 24EPS +37.66%·Rev n/aQ1 24EPS -22.95%·Rev n/aQ4 23EPS +6.00%·Rev n/aQ3 23EPS +13.04%·Rev n/a⚠ consensus missing

Atea Pharmaceuticals, Inc. AVIR

Jonae Barnes — Investor Relations or Corporate Communications

Jean-Pierre Sommadossi — Chief Executive Officer (CEO)

Arantxa Horga — Executive or Senior Manager (likely in clinical or medical affairs)

Janet Hammond — Executive or Senior Manager (likely in medical or clinical affairs)

John Vavricka — Executive or Senior Manager (likely commercial or business development)

Andrea Corcoran — Chief Financial Officer (CFO)

+7.0%1d on move date+4.7% vs SPY3d+2.4%5d+10.1%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AVIR calls or request research access.

More AVIR calls Browse calls Request research access